Foster City, CA, United States of America

Xiang Xu

This inventor holds 32 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 6 EPO patents, primarily in Data Management. Top assignees: Rigel Pharmaceuticals, Incorporated, Rubrik, Inc., Other. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiang Xu. Retrieved from https://idiyas.com/inventor/xiang-xu-kt00ik88

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 (Patent Applications = 7)

% Patents Active = 71.9

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 1)

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 63(Granted Patents)

Location History:

San Francisco, CA (US) (2003)
S. San Francisco, CA (US) (2004)
South San Francisco, CA (US) (2003 - 2014)
Foster City, CA (US) (2012 - 2021)

Company Filing History:

27 out of 492

Rigel Pharmaceuticals, Incorporated

1 out of 834,570

Other

patents

Years Active: 2003-2025

Loading Chart...

Areas of Expertise:

Multi-Tenancy

Data Management

Access Authorization

Carboxamide Compounds

AMPK Activators

Pharmaceutical Compositions

Cell Cycle Proteins

Germinal Center Kinase

Methods of Use

Sulfonamide Compounds

Screening Methods

Rad9 Dephosphorylation

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12470564 - Federated login mechanisms for multi tenant role based access control (2025-11-11),

2. 12461947 - Access authorization for report data in a multi-tenancy data management system (2025-11-04),

3. 12411835 - Access authorization for audit information in a multi-tenancy data management system (2025-09-09),

4. 12367110 - Multi-tenancy for large scale data management (2025-07-22),

5. 11174246 - Direct AMPK activators (2021-11-16),

6. 9353111 - Carboxamide compounds and methods for using the same (2016-05-31),

7. 9255085 - Carboxamide compounds and methods for using the same (2016-02-09),

8. 9181220 - N-substituted-heterocycloalkyloxybenzamide compounds and methods of use (2015-11-10),

9. 9174964 - AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same (2015-11-03),

10. 9062052 - Carboxamide compounds and methods for using the same (2015-06-23),

11. 8895578 - Carboxamide, sulfonamide and amine compounds and methods for using the same (2014-11-25),

12. 8871770 - Carboxamide compounds and methods for using the same (2014-10-28),

13. 8846600 - Carboxamide compounds and methods for using the same (2014-09-30),

14. 8785449 - Carboxamide compounds and methods for using the same (2014-07-22),

15. 8697727 - N-substituted-heterocycloalkyloxybenzamide compounds and methods of use (2014-04-15),

Title: Innovator Spotlight: Xiang Xu and His Contributions to Pharmaceutical Science

Introduction

Xiang Xu, based in Foster City, CA, is a prominent inventor in the field of pharmaceutical sciences with an impressive portfolio of 28 patents. His innovative work primarily focuses on the activation of AMPK pathways, contributing to the development of potential treatments for various medical conditions.

Latest Patents

Two of Xiang Xu's latest patents showcase his groundbreaking research. The first patent, titled "Direct AMPK Activators," discloses benzimidazole compounds along with pharmaceutical compositions and methods of use. One embodiment of this patent describes a compound structure capable of activating the AMPK pathway, which can be instrumental in the treatment of diseases linked to metabolic functions.

The second patent, "Carboxamide Compounds and Methods for Using the Same," introduces carboxamide compounds and their applications in pharmaceutical compositions. Similar to his previous work, this invention focuses on compounds that activate the AMPK pathway, providing promising avenues for addressing metabolism-related disorders and conditions.

Career Highlights

Throughout his career, Xiang Xu has made significant strides in the pharmaceutical industry. He has worked for Rigel Pharmaceuticals, where he further refined his expertise in drug development and innovation. His extensive background and commitment to research underscore his reputation as a thought leader in the field.

Collaborations

Xiang Xu collaborates closely with fellow innovators and researchers, including Rajinder Paul Singh and Hui Hong. These partnerships enhance the collective knowledge and drive forward the pursuit of innovative solutions within pharmaceutical sciences.

Conclusion

In summary, Xiang Xu stands out as a pivotal figure in the realm of pharmaceutical innovation, with a strong portfolio of patents that enhance our understanding of metabolic pathways and potential therapies. His dedication to developing compounds that activate the AMPK pathway positions him at the forefront of medical research, paving the way for future breakthroughs in treating metabolic disorders.

Profile summary based on public USPTO records.